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IntroductIon
Retroviral vectors (RVs) have been widely used to deliver therapeu-
tic genes in the context of gene therapy (GT) clinical applications 
for monogenic disorders, cancer, and infectious diseases provid-
ing stable and efficient expression of the transgene to patients.1–5 
Although  clinical  trials  for  primary  immunodeficiencies  have 
clearly demonstrated the therapeutic benefit of retroviral-based 
approaches4–11 the field of GT was significantly impacted by the 
sudden occurrence of severe adverse events linked to insertional 
mutagenesis  due  to  aberrant  vector-on-host  interactions.7,12–15 
Thus, insertional profiling, aimed at identifying vector integration 
sites and studying their potential impact in preclinical and clinical 
samples, has become an important tool to evaluate the global safety 
profile of clinical trials.12,13,16–22 Several groups including ours are 
currently working to improve insertion retrieval techniques and 
analysis in order to collect relevant information from integration 
site distribution. The results of these studies are exploited for the 
design of vectors and the set up of gene transfer protocol with the 
aim to couple efficient and regulated transgene expression with 
a safe insertion profile.1 In parallel with these efforts now is the 
appropriate time to retrospectively analyze in details the data col-
lected in the past years from vector integration studies with the 
goal to provide a proper rendering of the biological impact of ret-
roviral insertions. This review aims to re-evaluate the information 
available from clinical insertional profiling of RVs with a particu-
lar eye on the controversial findings and open issues impacting 
the common interpretation of data derived from integration sites 
analyses.
GenotoxIcIty In Gt clInIcal trIals
The potential genotoxicity of RV came to the attention of the GT 
community after the occurrence of severe adverse events in two 
clinical trials for X-linked severe combined immunodeficiency 
(SCID-X1). In these patients autologous bone marrow hematopoi-
etic stem/progenitor cell were transduced ex vivo with a Moloney 
leukemia  virus  (MLV)-derived  vector  carrying  the  common 
γ-subunit  of  interleukin-2  receptor-γ  (IL2RG)  under  the  long 
terminal repeat (LTR) promoter. The cells were reinfused back 
without any preparative conditioning.7,8 Overall, 17 out of the 20 
SCID-X1 patients enrolled in both clinical trials benefited from 
GT,  with  sustained  transgene  expression  and  immunological 
reconstitution.7,23,24 However, the success of SCID-X1 GT was mit-
igated by the occurrence of serious adverse events.13 Four patients 
in the French trial and one in the English trial developed clonal 
T-cell proliferation that became evident 2–6 years after treatment. 
Characterization  of  the  leukemic  clones  revealed  the  presence 
of integration sites in proximity of SPAG6, CCND2, and LMO2 
genes, and uncovered a significant LMO2 overexpression in the 
transformed  cells.12  The  aberrant  T-cell  proliferation  in  these 
patients  was  associated  with  the  transactivation  of  this  proto-
oncogene by vector enhancer sequences present on the LTR.16
LMO2  is  normally  expressed  in  hematopoietic  stem  cells 
(HSCs) and very early T-cell precursors while it is usually down-
regulated upon differentiation and its locus is involved in chromo-
somal translocation in cases of acute T-cell leukemia (T-ALL).25 
Although vector integrations close to LMO2 gene were found to 
reside within FRA11E, a common fragile site26 and chromosomal 
aberrations were detected in the expanded clones, the phenotype 
of such clones could not be associated with T-ALL.13 In addition, 
no overexpression of IL2RG or constitutive activation of down-
stream signaling molecules were observed in leukemic T cells 
from patients. Gain-of-function mutations of the transgene were 
also excluded by sequencing of the integrated provirus.12
Besides these findings, the causative role of vector-  mediated 
transactivation on proto-oncogenes is still controversial. Indeed, 
evidence supports the hypothesis that RV-driven IL2RG expression 
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may  synergistically  cooperate  with  oncogenic  transformation, 
possibly influencing T-cell differentiation.27,28 In addition, it has 
been suggested that, at least in murine models of SCID-X1, the 
non-regulated expression of this transgene could by itself drive to 
leukemogenesis without any additional integration-related influ-
ence,29 even if, in other studies, vector-mediated IL2RG expres-
sion was not able to affect normal T-cell development.30,31 Other 
oncogenic factors may reside on the disease-related clonal kinetics 
where abnormal population of lymphoid progenitor cells arrested 
in their differentiation path may accumulate additional mutations 
in the bone marrow during lymphoid reconstitution. A recent 
report raised an alternative possibility that lymphomagenesis in 
SCID-X1  could  have  been  independent  from  both  insertional 
mutagenesis and IL2RG overexpression suggesting the existence 
of other ill-defined risk factors for oncogenesis, including replica-
tive stress.32 The recent description of a leukemia case from the 
Wiskott–Aldrich syndrome (WAS) GT trial associated to a LMO2 
insertional activation raised again the interest in the specific inter-
action of RVs and this particular locus.33,34
Another insertional mutagenesis effect of RV leading to aber-
rant clonal proliferation in patients arose in the context of a GT trial 
for chronic granulomatosis disease (CGD). CGD is a rare inherited 
immunodeficiency caused by a functional defect in the microbial 
killing activity of phagocytes. The clinical protocol used in this 
trial was based on ex vivo retroviral gene transfer of gp91phox 
complementary DNA into mobilized peripheral blood CD34+ cells 
through a γ-RV.35 Autologous cell transfer of the gene-  corrected 
CD34+ cells was able to restore enzymatic activity in transduced 
phagocytes as testified by the clinical resolution of   bacterial and 
fungal infections in three treated patients.14,36 However, the high 
level of correction achieved, resulted from an unexpected in vivo 
expansion of gene-corrected myeloid cells showing clusters of vec-
tor integrations in the MDS-EVI1, PRDM16, and SETBP1 loci.14 
The relative contribution of each   single clone carrying these inte-
grants changed overtime, none  theless maintaining a sort of stabil-
ity in the most dominant clones.
The efficacy of GT was lost upon a progressive decrease of 
transgene expression on dominant clones due to methylation of 
the  viral  promoter.15  Concomitantly,  the  three  treated  patients 
developed a myelodysplasia with monosomy 7 and one of them 
died of overwhelming sepsis 27 months after GT.37 It has been 
recently hypothesized that the overexpression of EVI1 gene by 
insertional activation could have led to disruption of normal cen-
trosome duplication resulting in genomic instability, monosomy 
7, and clonal progression towards aberrant expansion and myelo-
dysplasia.15 In this case, the strong enhancer activity of the spleen 
focus-forming virus (SFFV) LTR may have further favored the 
transactivation of EVI1 gene to oncogenic expression levels.
Indeed,  another  GT  trial  for  CGD,  based  on  the  use  of  a 
γ-retroviral construct not carrying the SFFV promoter element, 
did not show any sign of clonal outgrowth with evidence of normal 
hematopoiesis maintained overtime in all the patients treated.38 
Thus, some of the different outcomes among the GT trials may 
be related to the strength of LTR enhancer sequences included 
in the vector constructs. It is also possible that the unregulated 
expression of gp91phox transgene particularly in the hematopoi-
etic  stem/progenitor  cell  compartment  could  have  contributed 
to DNA damage by reactive oxygen species production,36 mak-
ing desirable further improvement in vector design. On this line, 
animal models may be useful for studying normal hematopoietic 
dynamics independently from transgene and disease background. 
Indeed, Calmels et al. were able to detect a strong common inser-
tion site (CIS) in MDS-EVI1 locus in myeloid lineages not lead-
ing to clonal imbalances years after infusion in rhesus macaque, 
through the use of an MLV vector carrying a marker “neutral” 
transgene in a disease-independent setting.39
To  overcome  some  of  the  potential  issues  associated  with 
integrating  vectors,  self-inactivating  retroviral  and  lentiviral 
constructs have been developed which should carry a safer pro-
file as compared to γ-RVs.40,41 These constructs are specifically 
designed to reduce the probability of vector-mediated transacti-
vation of neighboring genes by the elimination of the enhancer 
sequences from viral LTRs. The tendency of lentiviral vectors to 
integrate inside transcriptional units but not in promoter regions, 
differently from γ-RVs,42,43 could play a role in reducing their cel-
lular transformation potential. On this line, a direct comparison 
between SIN-MLV and MLV with full-length LTR should allow 
dissecting the influences of vector distribution and of the activ-
ity of vector enhancer sequences on genotoxicity potential of RV 
constructs.
Clinical applications of lentiviral vector constructs was first 
achieved  for  the  treatment  of  X-linked  adrenoleukodystrophy 
(ALD)11 and β-thalassemia,41 and more recently for metachro-
matic leukodystrophy and WAS.1 The first two studies showed 
clear therapeutic benefit in the few patients treated, leading to 
the arrest of disease progression in ALD patients and transfusion 
independence in a thalassemia patient. However, in the latter trial 
the appearance of a self-limiting dominant clone in the myeloid 
compartment of a β(E)/β(0)-thalassemia individual was of some 
concerns. In this clone, a transcriptional activation of HMGA2 
occurred due to vector-mediated generation of a truncated tran-
script.39 Indeed, a recent study in mice carrying a truncated form 
of HMGA2 showed how an overexpression of the transcript is 
associated with the development of proliferative hematopoiesis 
and clonal expansion.44 Nevertheless, in the absence of clinical 
evidences supporting the existence of a preleukemic state or a sig-
nificant hematopoietic imbalance, this finding could still be inter-
preted as a stochastic event or as the result of a “benign” clonal 
expansion. A long-term follow up of the expanded clone in the 
thalassemia patient will be important to exclude the generation of 
potential clonal aberrancies in the future.
On the other hand, the GT approaches for adenosine deami-
nase-severe combined immunodeficieny (ADA-SCID) developed 
in the last years constitute to date an example of disease correction 
by γ-RV in absence of long-term vector-driven genotoxicity.10,45 
Over the last 10 years, more than 30 ADA-SCID patients have 
been treated with GT in different centers displaying in most cases 
significant  benefits  from  the  treatment  both  at  metabolic  and 
immunological levels and, importantly, not showing any case of 
leukemia.46 Data from these trials could provide information on a 
more neutral interaction between RVs and host genome, although 
the selective advantages of gene-corrected lymphocytes in ADA-
SCID should be taken into account as a bias to the general distri-
bution of RV insertions overtime.Molecular Therapy  vol. 20 no. 4 apr. 2012  711
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The  high  incidence  of  insertional  mutagenesis  events  in 
SCID-X1, CGD and recently WAS trials has raised the attention 
of the GT community to the importance of performing integra-
tion site analysis and has called for immediate investigation of the 
insertional profile of RVs in clinical applications. The presence of 
clusters of insertions in vivo, the detection of integration sites in 
proximity of proto-oncogenes, the contribution of each integrant 
to the pool of transduced cells are now among the main issues 
to be addressed for the safety assessment and follow up of GT 
clinical trials. A careful review of data collected from integration 
site analysis in GT trials should allow delving deeper into each of 
these topics with the goal to lead to a more precise interpretation 
of the results of GT clinical approaches.
cIs
Early  studies  exploited  oncogenicity  mediated  by  retroviruses 
to  tag  specific  insertion  sites  correlated  with  experimentally 
induced  tumors  in  animal  models.47–50  Upon  aberrant  selec-
tion of transduced cells, retroviral integrations were recurrently 
located and clustered in specific regions called CIS. These loci 
were defined on the basis of specific frequency of insertions into 
given genomic windows (e.g., more than two independent inser-
tions in 50 kb, more than three insertions in 100 kb, more than 
four in 200 kb etc.).
According  to  these  observations,  studies  were  designed  to 
analyze the incidence of CIS detection in vivo considering this as a 
fundamental parameter for measuring the safety of GT protocols. 
In this regard, assessing the genotoxic potential of retroviral ver-
sus lentiviral vectors Montini et al. were able to show that accel-
eration of tumor onset in tumor-prone mice was associated with 
the detection of CIS in transformed cells.40 Indeed, the early inte-
gration site profiling from GT clinical trials had already showed 
clusters of insertions in vivo from GT treated patients unveiling 
in some cases a strong correlation with the occurrence of severe 
adverse events.17,21 As above mentioned, a number of insertions 
into the MDS-EVI1 or PRDM16 locus were found in strongly 
dominant myeloid clones from the two chronic CGD GT treated 
patients.14 The LMO2 and CCND2 loci were instead related with 
the development of leukemia cases in a total of five patients from 
two GT trials for SCID-X1, being CIS in both the trials.16,18 Similar 
findings were recently shown in the context of the clinical trial for 
WAS 6 in which it was reported a high incidence of vector integra-
tions in these loci. This data supports a possible link between the 
presence of CIS and an increased risk for patients of developing 
aberrant clonal selection in vivo.
However, when an attempt was made in the French SCID-X1 
trial to stratify the patients in individuals who developed leukemia 
versus those that did not, according to their integration profile,17 
the authors commented that “it was not possible to distinguish 
retroviral insertion sites in patients with lymphoproliferation from 
those without and CIS of third order or higher were spread over 
these two groups of patients”. Moreover, CIS were even conserved 
among diverse GT clinical trials with different outcomes. The very 
same regions involved by genotoxic integrations in the SCID-X1 
trials were also found at the same frequency in the ADA-SCID GT 
without leading to any abnormal expansion in patients.19 In the 
same study, CIS were also detected with comparable percentages 
in transduced hematopoietic stem/progenitor cell before infusion 
in patients while another study confirmed the presence of inser-
tional hotspots in transduced human hematopoietic progenitors 
in vitro just after transduction.51 Our group recently unveiled the 
epigenetic features at the basis of these in vitro insertional prefer-
ences showing that they are cell-specific and physiologically main-
tained in patients even many years after GT in absence of adverse 
events.20
Following this line, a possible explanation for the detection of 
CIS could depend on the intrinsic biases of the RV vectors that 
integrate in favored genomic loci at the time of entry into the tar-
get cell. Therefore, in the context of GT trials a proper comparison 
between in vitro and in vivo data from GT patients is fundamental 
to draw conclusions on integration site selection. The occurrence 
of a clonal skewing in  vitro, due to vector enhancer\promoter 
activity before reinfusion, could give rise to potential biases, but 
the short culture time (around 3–4 days in most of the protocols) 
makes this event unlikely. Other potential caveats of integration 
site  analysis  are  related  to  the  heterogeneous  composition  of 
transduced CD34+ cells of which long-term HSC represents only 
a small fraction. This cell heterogeneity may impact both the vec-
tor distribution in vitro and the detection of CIS in vivo due to the 
vector effects on specific progenitors, whose proportion may vary 
among the trials.
Still, some of the CIS are specifically detected only after in vivo 
selection, while are not detectable in vitro at the time of transduc-
tion. Indeed, an alternative mechanism leading to CIS identifica-
tion in vivo (not related to vector genotoxicity) could be linked 
to  the  transgene  activity.  One  could  speculate  that  expression 
variegation, due to positional effects, could confer different sur-
vival potentials to different clones. In this respect transcriptionally 
active regions could influence transgene expression and provide 
selective advantages to certain gene-corrected cells. As a conse-
quence, a higher proportion of clones carrying integrations in 
these loci could be found in vivo overtime with the appearance 
of “benign” CIS on the integration profiles of GT patients. We 
recently suggested that these nongenotoxic CIS could be detected 
in  the  ADA-SCID  GT  where  gene-corrected  cells  expressing 
higher levels of the ADA transgene, possibly due to the high tran-
scriptional activity of the regions hosting the integration sites, 
have a selective advantage in vivo through better detoxification 
from ADA substrates.20
In the attempt to dissect the different origins of CIS, a recent 
work exploiting datasets of integration sites from experimental 
models and an ALD lentiviral GT trial11 suggested that the dis-
tribution of integration sites along the CIS could be predictive of 
their genotoxic potential.52 The identification of “sharp peaks” of 
insertions targeting a single gene has been suggested to constitute 
the “worst” CIS configuration. Another study recently showing an 
integrated analysis of >7,000 insertion sites previously retrieved in 
the context of multiple clinical approaches, revealed the presence 
of shared CIS among the trials and pointed at a restricted num-
ber of specific loci as preferential targets for retroviral integrations 
in vitro and in vivo.53 These types of bioinformatic approaches 
with the meta-analysis of big insertion site databases available in 
the literature will be of help in the future to unveil the real nature 
of CIS detection in GT applications.712  www.moleculartherapy.org  vol. 20 no. 4 apr. 2012   
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Proto-oncoGenIc HIts
For safety assessment of GT, the ontology and functional charac-
teristic of genes close to the insertion sites represent an impor-
tant parameter. The in  vivo detection of vector integrations in 
proximity of genes involved in growth control or associated with 
transformation events is generally considered a hint of a poten-
tially aberrant clonal selection. Indeed, early retroviral tagging 
experiments  in  mice  showed  how  integrations  isolated  from 
tumor cells were often located in proximity of growth-promoting 
genes,48 thus, providing a number of candidate proto-oncogenes 
now listed in the retroviral tagged cancer gene database (RTCGD, 
http://rtcgd.ncifcrf.gov/).
More recently, different groups have also observed the asso-
ciation of insertions in proximity of particular gene functional 
categories (such as cell-cycle control, apoptosis signaling or tran-
scriptional regulation) with clonal dominance, in the context of 
in vitro and in vivo genotoxicity assays.40,54,55 A list of genes derived 
from  in  vitro  clonal  dominance  assays  (insertional  dominance 
database) was built as an additional reference for vector biosafety 
studies in human GT.55 On the basis of this information, it was 
generally assumed that a high incidence of vector integrations in 
these regions can be associated to an increased risk of developing 
aberrant clonal selection in vivo.
However, one should be reminded that most of the so-called 
“growth-promoting” genes or proto-oncogenes could be also more 
neutrally defined as “stemness” genes since they are in general 
highly expressed in stem cells bearing self-renewing capacity. This 
was indeed pointed out in the work by Kustikova et al. where inte-
grations in dominant clones were reported to significantly mark 
“stemness” pathways.55 This feature is of particular relevance for 
MLV vectors which, in absence of any strong in vivo clonal selec-
tion, display a tendency to land into certain stem cell associated 
loci in vitro due to the transcriptional activity and epigenetic sta-
tus of hematopoietic progenitors at the time of transduction.20,51
These insertional preferences could explain why different GT 
trials, irrespectively to their outcomes, displayed the same vector 
bias for genomic regions like LMO2 and EVI1, which are highly 
active in hematopoietic progenitors.56,57 Indeed, by tracking LMO2 
integrations overtime in different patients from our ADA-SCID 
GT trial, we showed that the relative clonal contribution of these 
integrants was maintained below 1% of all transduced T cells over 
a long period of time after GT.19 More recently, we found that this 
locus is a target for retroviral integrations only in HSC, where sev-
eral histone modifications markers reflecting an open chromatin 
configuration are suggestive of a high accessibility of this region to 
integration events.20
In any case, analyzing the frequency of potentially dangerous 
insertions into the genome represents only an indirect measure 
of the genotoxic potential of integrating vectors. A more precise 
indication of insertional genotoxicity would come from a detailed 
study of the consequences of a specific integration on cell   behavior 
in clinical samples. However, studying potential vector-mediated 
transactivation of proto-oncogenes as a first hit mechanism for 
cellular  transformation  in  patients,  before  the  development  of 
aberrant  expansion,  has  been  a  difficult  task.  Indeed,  by  the 
  analysis of single T-cell clones isolated ex vivo from patients, two 
independent studies were not able to show major vector-mediated 
perturbations of cellular genes.58,59 In addition, even when these 
events were detected they did not have any influence on cellular 
behavior or growth rate, possibly because these subtle changes 
in the transcriptome could be below the hypothetical threshold 
required for the induction of transformation events. The detection 
of additional mutations after, and not before, the proto-oncogenic 
vector  perturbation  could  also  help  explain  these  contrasting 
findings, but so far, no study was able to show the consequential 
appearance of these events upon retroviral insertions in vivo before 
aberrant expansions. Furthermore, it was not formally shown that 
a cell bearing a particular insertion site could become more sus-
ceptible to additional independent mutations and acquire a higher 
spontaneous mutation rate. Indeed, the long-term observations in 
ADA-SCID GT patients have revealed that the integration of RV 
into regions associated with leukemic events is not per se sufficient 
to give rise to clonal aberrant expansion in patients.19
In summary, the detection of insertions into proto-oncogenes, 
namely “stemness” genes, in vivo in HSC GT could also be consid-
ered as a reflection of what is a general physiological “insertional 
footprint” of gene-corrected hematopoietic stem cell at the time of 
transduction. Following this line, the biological interpretation of 
insertion site distribution from patients’ samples would strongly 
benefit from a thorough profiling of integrations coupled with 
an in-depth analysis of target cell transcriptome and epigenome 
before infusion.60
clonal QuantIFIcatIon oF Gene-corrected 
cells
To date, ligation-mediated PCR (LM-PCR) or linear amplifica-
tion-mediated PCR (LAM-PCR) are the most exploited meth-
ods to retrieve integration sites from transduced cells. Both the 
technologies are based on the digestion of genomic DNA with 
restriction enzymes, the ligation of a linker cassette and the expo-
nential amplification of vector-genomic junctions through prim-
ers annealing on the final LTR portion and the linker cassette 
itself.61 The final PCR products are then sequenced in order to col-
lect and map the regions flanking the vector LTR, retrospectively 
identifying the integration sites on the genome of reference. The 
early protocols based on shotgun cloning into competent bacteria 
and Sanger sequencing have been replaced with more efficient and 
cost-effective methods such as the barcode tagging of LAM-PCR 
products from different cell sources followed by pyrosequencing 
of the pooled samples.22
The idea that data generated by LAM-PCR in combination 
with high-throughput sequencing are highly representative of the 
clonal contribution of each integrant in a given sample has been 
the origin of some potential misinterpretation of data derived 
from the clinics. The appearance of a gel run of LAM-PCR prod-
ucts from an in vitro transduced bulk population is generally a 
smear of undistinguishable bands corresponding to several hun-
dred  thousands  diverse  integration  sites.  Differently,  samples 
purified from patients, years after infusion of gene-corrected cells, 
show more discrete bands with different intensities corresponding 
to a more limited number of transduced clones engrafted in vivo. 
The clonal contribution of gene-corrected cells in the context of 
GT clinical follow up is generally gathered from the appearance of 
oligoclonal or polyclonal repertoires of LAM-PCR products.16–19,21 Molecular Therapy  vol. 20 no. 4 apr. 2012  713
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It is then commonly believed that the different intensities of the 
gel bands (and as a consequence the different relative sequence 
counts obtained form high-throughput sequencing) are somehow 
linked to the clonal contributions of each integration site in the 
original cell pool.
Clonal dominance occurring in vitro in preclinical assays was 
associated to a reduction in the polyclonality of LAM-PCR prod-
ucts and an increased intensity of single bands overtime.54 The 
sequence counts of vector-genome junctions from 454 sequenc-
ing correlated well with the dynamics of the leukemic clones bear-
ing LMO2 integrations in the high-throughput analysis of samples 
from one SCID-X1 GT trial in patients before and after chemo-
therapic treatment.16 More recently the relative abundance of a 
clone carrying an insertion in the HMGA2 locus was also mea-
sured by means of sequence counts in the β-thalassaemia patient 
treated with lentiviral GT.41 Thus, is the low diversity and relatively 
high contribution of single LAM-PCR products in a cell pool 
predictive of a potentially skewed profile with dominant clones 
emerging from a mixed transduced population?
To  fairly  answer  this  question  it  is  important  to  take  into 
account that the LAM-PCR technique itself has specific techni-
cal biases linked to the use of restriction enzymes.62 For example, 
the same sample could show few or many bands according to the 
cutting frequency of the enzymes used in the LAM-PCR protocol. 
This technical constraint affects not only the number of unique 
bands but also their relative intensity and ultimately the number 
of reads retrieved from high-throughput sequencing for each par-
ticular vector-genomic junction. As a consequence, a given inte-
gration site could be more easily retrieved due to its proximity to 
a specific restriction site and along the LAM-PCR protocol more 
favorably amplified and sequenced irrespectively of the contri-
bution of the relative clone in the original cell pool. Indeed, the 
group of Christopher Baum reported recently that, in the absence 
of self-evident clonal expansions, there is often a strong discrep-
ancy between insertion site frequency measured by 454 sequenc-
ing and the results of specific quantitative PCR designed on the 
same vector-genome junctions.63 This aspect should be carefully 
taken into account since many groups are now exploiting more 
than one restriction enzyme for LAM-PCR protocols that are then 
differently biased.
Overcoming some of these issues, a significant improvement of 
LAM-PCR technology has been recently proposed by Paruzinsky 
et al.64 The authors showed the exploitation of a restriction site-
independent method of insertion site retrieval, which proved to 
be efficacious but yet limited by the amount of DNA required for 
the analysis. Another unbiased method for the recovery of inte-
gration sites is based on a phage Mu-mediated introduction of an 
adaptor  sequence  allowing  the  amplification  of  vector-genome 
junctions without the need for restriction enzymes.65 This proto-
col has been exploited with success to estimate the relative abun-
dance of gene-modified cells in clinical trials samples. Additional 
technologies providing a theoretically unbiased high-throughput 
access to the genome have been recently developed based on soni-
cation of genomic DNA.66 Once these and other new nonrestric-
tive platforms will be consolidated in terms of sensitivity they 
should provide the techniques of choice for future vector integra-
tion studies.
Importantly, sequence counts of vector-genome junctions may 
be informative of the relative frequency of a clone bearing a given 
insertion only within the population of gene-corrected cells but 
not on the whole set of blood cells in a given lineage. Thus, before 
drawing conclusions on a clonal amplification of potential clinical 
relevance, a relatively high sequence count (e.g., 30% of the total 
sequencing reads) should be always normalized to the frequency 
of transduced cells in the analyzed sample (which in some cases is 
less than 5% of the total cell population in the patient).
InteGratIon sIte analysIs and next  
GeneratIon seQuencInG
Despite the caveats and the open questions, over the past years the 
analysis of integration profiles in retroviral-based GT has allowed 
investigators to address several issues related to insertional geno-
toxicity and safety of GT approaches.6,16–21,40,55 The next generation 
sequencing technologies have dramatically boosted these studies 
by exponentially increasing the amount of insertion sites available 
for in-depth analysis.
The other side of the coin is the potential “toxicity of infor-
mation” deriving from the overflow of data originated from deep 
sequencing. There is already a strong requirement for the devel-
opment of new tools both for the automatic processing of raw 
sequences and for the algorithms downstream of the analysis pipe-
line. A proper handling of the sequence datasets is now required 
to effectively manage thousands of sequencing reads at one time. 
A major challenge to this approach will be the storage and use of 
large amount of sequence data, which will require an integrated 
platform  of  database  structures  flexible  to  the  future  develop-
ment of sequencing technologies. The next years will also see an 
increasing demand for more refined tools to discriminate between 
bona fide vector-genomic junctions and by-products derived from 
LAM-PCR/deep sequencing systematic biases. Indeed, although 
extremely time and cost-effective high-throughput technologies 
still carry an average error rate significantly higher than the typi-
cal observed from high-quality Sanger sequencing.67 Downstream 
analysis  will  also  need  to  be  adapted  to  the  size  of  the  deep 
sequencing data to avoid misinterpretations.
A  prototypical  example  involves  the  identification  of  CIS. 
When statistical algorithms designed for low-throughput gener-
ated databases are exploited for the detection of cluster of inser-
tions in larger insertional data, the incidence of CIS could be 
over-estimated, and may lead to not fully statistically supported 
biological conclusions. Concerns about the statistical definition of 
CIS were already raised in the early insertion site analysis68 and 
in a work based on a meta-analysis of all the CIS identified from 
retroviral tagging experiments and listed in the retroviral tagged 
cancer gene database (RTCGD).69 By the development of a kernel 
convolution framework, de Ridder and co-authors were able to 
detect CIS in a noisy environment while controlling the probability 
of detecting false clusters of insertions. Strikingly, they found that 
53% of the previously defined CIS did not reach the significance 
threshold in this setting. To date, the genomic windows initially 
established for the characterization and identification of CIS are 
in many case too wide to properly define an insertional hotspot 
and they should be adapted in terms of distances between two or 
more insertion sites to the currently available databases. On this 714  www.moleculartherapy.org  vol. 20 no. 4 apr. 2012   
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line, new statistical tools for CIS definition are under development 
for the analysis of large insertional datasets.20,52,70,71
tHe Future oF InteGratIon ProFIlInG
Although in the next years insertion site analysis will still gener-
ate information relevant to the GT field, the impact of these data 
will  progressively  broaden  to  address  more  general  biological 
question.
An obvious extension of these studies is based on the use 
of  integration  site  analysis  to  get  new  insights  on  the  biol-
ogy of wild-type retroviruses with a particular focus on HIV. 
Indeed,  increasing  amount  of  data  from  insertional  profiling 
have been produced along the last years enlightening molecular 
aspect linked to tethering, nuclear transportation, and latency 
of HIV.72–75 To date, one of the best-supported models of HIV 
shuttle to nucleus, involves interactions between HIV integrase 
(IN) and LEDGF/p75 protein.76,77 A study based on insertional 
profiling of wild-type HIV on cells lacking LEDGF/p75 showed 
reduced frequency of integration in transcription units72 propos-
ing a tethering function of LEDGF/p75 through the binding of 
IN. However, since the reduction in targeting of genes appeared 
overall modest, the IN–LEDGF/p75 interaction did not seem to 
fully explain HIV integration preferences, indicating that other 
molecules may be involved. A more recent work showed that 
depletion of transportin-3 and RanBP2 altered integration tar-
geting for HIV suggesting a role of these molecules in the nuclear 
transportation of HIV.75 Another integration site analysis was 
also able to address issues regarding the latency of HIV. Working 
on the hypothesis that integration in resting cells may contrib-
ute to formation of the latent reservoir, Brady et al. showed that 
HIV insertions were more frequently found in relatively less 
gene-dense regions in resting cells than in activated cells, sug-
gesting that, when landing in such gene deserts HIV, may be 
more  prone  to  forming  latent  proviruses.74  High-throughput 
genetic and epigenetic mapping combined with refined inser-
tion site analysis will be in the next years crucial to extrapolate 
more factors involved in HIV insertional mechanism potentially 
uncovering molecular elements with a pivotal role in HIV life 
cycle and reactivation.
Integration site analysis has also been exploited to uncover 
the properties of Zinc-finger nucleases (ZFNs) molecules. ZFNs-
based technology is able, by introducing a double-strand break at 
a predetermined locus, to drive efficiently site-specific integration 
of a transgene of interest in human target cells.78–80 Until recently, 
a direct genome-wide measurement of the degree of specificity 
of ZFNs activity at the desired locus was missing. By combining 
ZNFs with an integrase-defective lentiviral vector, Gabriel et al. 
were able to tag the sites of double-strand breaks and to retrieve 
the insertions of integrase-defective lentiviral vector with con-
ventional  LAM-PCR/pyrosequencing-based  techniques.81  Thus, 
insertion profiling has allowed studying with unprecedented reso-
lution the incidence of ZFNs off-target activity moving the tech-
nology forward towards its application in translational research. 
Studies based on integration site analysis will be important to 
provide information for the utilization of new molecular tools in 
the clinic, as well as to enlighten new mechanisms at the basis of 
protein–DNA interactions.
A  broader  application  of  integration  profiling  involves  the 
exploitation  of  specific  integrants  as  tags  to  track  single  cell 
clones in vivo. Upon transduction each target hematopoietic cell 
becomes marked by a unique vector integration site, which will 
be inherited by all its progeny. Consequently, if two or more cell 
clones belonging to different lineages share an identical integra-
tion, it is likely they are derived from a common upstream pro-
genitor. Based on this principle, insertion site analysis of different 
hematopoietic lineages after infusion of transduced cells, could 
provide a unique tool to study in vivo hematopoietic progenitors 
survival, fate decisions, and dynamics overtime directly in patients. 
Indeed, while it has long been established that multipotent, self-
renewing HSCs sustain the lifelong replenishment of the whole 
mature blood cell compartment, the complete hierarchy of human 
hematopoiesis  is  still  far  from  being  elucidated.82–86  Reaching 
a consensus on a model of hematopoiesis has been hampered 
essentially by to the lack of experimental settings allowing high-
throughput clonal analysis of hematopoietic progenitors behav-
iour in vivo. Addressing this issue, retroviral insertion databases 
from SCID-X1 GT patients have been exploited to assess the long-
term clonal output of hematopoietic progenitors, up to 10 years 
after infusion of transduced cells.87 However, the limited lineage 
engraftment of transduced cells in patients, allowed only an esti-
mation of the clonal diversity of the reconstituted hematopoietic 
system based on a capture–recapture method applied to insertions 
retrieved from T cells. The ALD and WAS GT clinical trials,6,11 
showed instead a multilineage engraftment of gene-corrected cells 
up to 2 years postinfusion of transduced cells. A high degree of 
shared identical integrations between myeloid and lymphoid lin-
eages was observed, potentially marking multipotent progenitors 
but the analysis was performed at early timepoints, lacking a lon-
ger patients follow up.
To  draw  a  comprehensive  picture  of  human  hematopoi-
etic  dynamics  through  “insertional  tagging”  both  multilineage 
engraftment  and  long-term  follow  up  will  be  needed.  Indeed, 
only  under  these  conditions  the  detection  of  shared  identical 
integrations among bone marrow CD34+ progenitors and mul-
tiple myeloid and lymphoid lineages persisting overtime would 
identify, directly in humans, cell clones meeting the definition of 
long-term reconstituting HSCs. Similarly, the consistent finding 
of integrants shared between some hematopoietic lineages but not 
others, would indicate the persistence of marked lineage-  restricted 
progenitors. Monitoring these clones over defined periods of time 
in  humans,  as  performed  in  mice,88  would  provide  important 
information concerning the lifespan and possible fluctuations in 
lineage output of hematopoietic progenitors.
On this line, a promising tool for quantitative and unbiased 
studies in a mixed population of transduced cells is represented by 
retroviral oligonucleotide barcoding, exploiting PCR and/or array-
based techniques to detect complex libraries of RVs with unique 
sequence tags,.65,89,90 Nonetheless, the exploitation of this technique 
remains to date confined to animal studies, since the utilization of 
vector libraries is not feasible in human GT applications.
conclusIons
Overall, in the coming years, studies based on integration site 
analysis  will  play  a  fundamental  role  in  answering  questions Molecular Therapy  vol. 20 no. 4 apr. 2012  715
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going from the basic biology to the translational research and 
clinical applications. The increasing amount of data will require 
investigators to deal with the potential overload of information 
by constantly reviewing and adapting the tools for the analysis of 
insertion sites at all levels. In addition, more insights from in vitro 
and in vivo experiments will be needed to solve the controversies 
associated with the functional role of vector–host interactions. 
These steps will be crucial to provide a proper interpretation of 
biological data while the technology of retroviral gene transfer is 
moving rapidly towards new and more complex applications.
acKnoWledGMents
The authors are grateful for support of our work by Italian Telethon 
Foundation, CLINIGENE-NoE, CELL-PID and EUROCGD (E-rare). We 
thank Kevin Goudy for his revision of the manuscript. The authors 
  declared no conflict of interest.
reFerences
1.  Naldini, L (2011). Ex vivo gene transfer and correction for cell-based therapies.  
Nat Rev Genet 12: 301–315.
2.  Rossi, JJ, June, CH and Kohn, DB (2007). Genetic therapies against HIV. Nat Biotechnol 
25: 1444–1454.
3.  Deeks, SG, Wagner, B, Anton, PA, Mitsuyasu, RT, Scadden, DT, Huang, C et al. (2002). 
A phase II randomized study of HIV-specific T-cell gene therapy in subjects with 
undetectable plasma viremia on combination antiretroviral therapy. Mol Ther  
5: 788–797.
4.  Mavilio, F, Pellegrini, G, Ferrari, S, Di Nunzio, F, Di Iorio, E, Recchia, A et al. (2006). 
Correction of junctional epidermolysis bullosa by transplantation of genetically 
modified epidermal stem cells. Nat Med 12: 1397–1402.
5.  Ciceri, F, Bonini, C, Stanghellini, MT, Bondanza, A, Traversari, C, Salomoni, M  
et al. (2009). Infusion of suicide-gene-engineered donor lymphocytes after family 
haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): 
a non-randomised phase I-II study. Lancet Oncol 10: 489–500.
6.  Boztug, K, Schmidt, M, Schwarzer, A, Banerjee, PP, Díez, IA, Dewey, RA et al. (2010). 
Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N Engl J Med  
363: 1918–1927.
7.  Hacein-Bey-Abina, S, Hauer, J, Lim, A, Picard, C, Wang, GP, Berry, CC et al. (2010). 
Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J 
Med 363: 355–364.
8.  Cavazzana-Calvo, M, Hacein-Bey, S, de Saint Basile, G, Gross, F, Yvon, E, Nusbaum, P 
et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 
disease. Science 288: 669–672.
9.  Aiuti, A, Vai, S, Mortellaro, A, Casorati, G, Ficara, F, Andolfi, G et al. (2002). Immune 
reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme 
replacement. Nat Med 8: 423–425.
10.  Aiuti, A, Cattaneo, F, Galimberti, S, Benninghoff, U, Cassani, B, Callegaro, L et al. 
(2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. 
N Engl J Med 360: 447–458.
11.  Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I 
et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked 
adrenoleukodystrophy. Science 326: 818–823.
12.  Hacein-Bey-Abina, S, Von Kalle, C, Schmidt, M, McCormack, MP, Wulffraat, N, 
Leboulch, P et al. (2003). LMO2-associated clonal T cell proliferation in two patients 
after gene therapy for SCID-X1. Science 302: 415–419.
13.  Hacein-Bey-Abina, S, von Kalle, C, Schmidt, M, Le Deist, F, Wulffraat, N, McIntyre, E 
et al. (2003). A serious adverse event after successful gene therapy for X-linked severe 
combined immunodeficiency. N Engl J Med 348: 255–256.
14.  Ott, MG, Schmidt, M, Schwarzwaelder, K, Stein, S, Siler, U, Koehl, U et al. (2006). 
Correction of X-linked chronic granulomatous disease by gene therapy, augmented 
by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 12: 401–409.
15.  Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A et al. 
(2010). Genomic instability and myelodysplasia with monosomy 7 consequent to 
EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16: 
198–204.
16.  Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E et al. 
(2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of 
SCID-X1. J Clin Invest 118: 3132–3142.
17.  Deichmann, A, Hacein-Bey-Abina, S, Schmidt, M, Garrigue, A, Brugman, MH, Hu, J  
et al. (2007). Vector integration is nonrandom and clustered and influences the fate of 
lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 117: 2225–2232.
18.  Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, 
H et al. (2008). Insertional mutagenesis combined with acquired somatic mutations 
causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118: 
3143–3150.
19.  Aiuti, A, Cassani, B, Andolfi, G, Mirolo, M, Biasco, L, Recchia, A et al. (2007). 
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID 
patients treated with stem cell gene therapy. J Clin Invest 117: 2233–2240.
20.  Biasco, L, Ambrosi, A, Pellin, D, Bartholomae, C, Brigida, I, Roncarolo, MG et al. 
(2011). Integration profile of retroviral vector in gene therapy treated patients is 
cell-specific according to gene expression and chromatin conformation of target cell. 
EMBO Mol Med 3: 89–101.
21.  Schwarzwaelder, K, Howe, SJ, Schmidt, M, Brugman, MH, Deichmann, A, Glimm, 
H et al. (2007). Gammaretrovirus-mediated correction of SCID-X1 is associated 
with skewed vector integration site distribution in vivo. J Clin Invest 117: 
2241–2249.
22.  Schmidt, M, Schwarzwaelder, K, Bartholomae, CC, Glimm, H and von Kalle, C (2009). 
Detection of retroviral integration sites by linear amplification-mediated PCR and 
tracking of individual integration clones in different samples. Methods Mol Biol 506: 
363–372.
23.  Fischer, A and Cavazzana-Calvo, M (2008). Gene therapy of inherited diseases. Lancet 
371: 2044–2047.
24.  Gaspar, HB, Cooray, S, Gilmour, KC, Parsley, KL, Adams, S, Howe, SJ et al. (2011). 
Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked 
severe combined immunodeficiency. Sci Transl Med 3: 97ra79.
25.  Rabbitts, TH (1998). LMO T-cell translocation oncogenes typify genes activated by 
chromosomal translocations that alter transcription and developmental processes. 
Genes Dev 12: 2651–2657.
26.  Bester, AC, Schwartz, M, Schmidt, M, Garrigue, A, Hacein-Bey-Abina, S, Cavazzana-
Calvo, M et al. (2006). Fragile sites are preferential targets for integrations of MLV 
vectors in gene therapy. Gene Ther 13: 1057–1059.
27.  Davé, UP, Jenkins, NA and Copeland, NG (2004). Gene therapy insertional 
mutagenesis insights. Science 303: 333.
28.  Davé, UP, Akagi, K, Tripathi, R, Cleveland, SM, Thompson, MA, Yi, M et al. (2009). 
Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias 
induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet 5: 
e1000491.
29.  Woods, NB, Bottero, V, Schmidt, M, von Kalle, C and Verma, IM (2006). Gene 
therapy: therapeutic gene causing lymphoma. Nature 440: 1123.
30.  Pike-Overzet, K, de Ridder, D, Weerkamp, F, Baert, MRM, Verstegen, MM, Brugman, 
MH et al. (2006). Gene therapy: is IL2RG oncogenic in T-cell development? Nature 
443: E5.
31.  Pike-Overzet, K, van der Burg, M, Wagemaker, G, van Dongen, JJ and Staal, FJ (2007). 
New insights and unresolved issues regarding insertional mutagenesis in X-linked 
SCID gene therapy. Mol Ther 15: 1910–1916.
32.  Ginn, SL, Liao, SH, Dane, AP, Hu, M, Hyman, J, Finnie, JW et al. (2010). 
Lymphomagenesis in SCID-X1 mice following lentivirus-mediated phenotype 
correction independent of insertional mutagenesis and gammac overexpression.  
Mol Ther 18: 965–976.
33.  Avedillo Diez, I, Zychlinski, D, Coci, EG, Galla, M, Modlich, U, Dewey, RA  
et al. (2011). Development of novel efficient SIN vectors with improved safety 
features for Wiskott-Aldrich syndrome stem cell based gene therapy. Mol Pharm  
8: 1525–1537.
34.  Trobridge, GD (2011). Genotoxicity of retroviral hematopoietic stem cell gene 
therapy. Expert Opin Biol Ther 11: 581–593.
35.  Ott, MG, Merget-Millitzer, H, Ottmann, OG, Martin, H, Brüggenolte, N, Bialek, H  
et al. (2002). Mobilization and transduction of CD34(+) peripheral blood stem cells in 
patients with X-linked chronic granulomatous disease. J Hematother Stem Cell Res 11: 
683–694.
36.  Grez, M, Reichenbach, J, Schwäble, J, Seger, R, Dinauer, MC and Thrasher, AJ (2011). 
Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther 
19: 28–35.
37.  Seger, RA (2010). Chronic granulomatous disease: recent advances in 
pathophysiology and treatment. Neth J Med 68: 334–340.
38.  Kang, EM, Choi, U, Theobald, N, Linton, G, Long Priel, DA, Kuhns, D et al. (2010). 
Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable 
long-term correction of oxidase activity in peripheral blood neutrophils. Blood 115: 
783–791.
39.  Calmels, B, Ferguson, C, Laukkanen, MO, Adler, R, Faulhaber, M, Kim, HJ et al. (2005). 
Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate 
hematopoietic cells. Blood 106: 2530–2533.
40.  Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Bartholomae, CC, Ranzani, M et al. 
(2009). The genotoxic potential of retroviral vectors is strongly modulated by vector 
design and integration site selection in a mouse model of HSC gene therapy. J Clin 
Invest 119: 964–975.
41.  Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F et al. (2010). 
Transfusion independence and HMGA2 activation after gene therapy of human 
ß-thalassaemia. Nature 467: 318–322.
42.  Mitchell, RS, Beitzel, BF, Schroder, AR, Shinn, P, Chen, H, Berry, CC et al. (2004). 
Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. 
PLoS Biol 2: E234.
43.  Wu, X, Li, Y, Crise, B and Burgess, SM (2003). Transcription start regions in the human 
genome are favored targets for MLV integration. Science 300: 1749–1751.
44.  Ikeda, K, Mason, PJ and Bessler, M (2011). 3’UTR-truncated Hmga2 cDNA causes 
MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC 
in mice. Blood 117: 5860–5869.
45.  Gaspar, HB, Cooray, S, Gilmour, KC, Parsley, KL, Zhang, F, Adams, S et al. (2011). 
Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe 
combined immunodeficiency leads to long-term immunological recovery and 
metabolic correction. Sci Transl Med 3: 97ra80.
46.  Ferrua, F, Brigida, I and Aiuti, A (2010). Update on gene therapy for adenosine 
deaminase-deficient severe combined immunodeficiency. Curr Opin Allergy Clin 
Immunol 10: 551–556.
47.  Shin, MS, Fredrickson, TN, Hartley, JW, Suzuki, T, Akagi, K, Agaki, K et al. (2004). 
High-throughput retroviral tagging for identification of genes involved in initiation 
and progression of mouse splenic marginal zone lymphomas. Cancer Res 64: 
4419–4427.
48.  Mikkers, H and Berns, A (2003). Retroviral insertional mutagenesis: tagging cancer 
pathways. Adv Cancer Res 88: 53–99.
49.  Kim, R, Trubetskoy, A, Suzuki, T, Jenkins, NA, Copeland, NG and Lenz, J (2003). 
Genome-based identification of cancer genes by proviral tagging in mouse retrovirus-
induced T-cell lymphomas. J Virol 77: 2056–2062.716  www.moleculartherapy.org  vol. 20 no. 4 apr. 2012   
© The American Society of Gene & Cell Therapy Retroviral Integrations in GT Trials
50.  Lund, AH, Turner, G, Trubetskoy, A, Verhoeven, E, Wientjens, E, Hulsman, D et al. 
(2002). Genome-wide retroviral insertional tagging of genes involved in cancer in 
Cdkn2a-deficient mice. Nat Genet 32: 160–165.
51.  Cattoglio, C, Facchini, G, Sartori, D, Antonelli, A, Miccio, A, Cassani, B et al. (2007). 
Hot spots of retroviral integration in human CD34+ hematopoietic cells. Blood 110: 
1770–1778.
52.  Biffi, A, Bartolomae, CC, Cesana, D, Cartier, N, Aubourg, P, Ranzani, M et al. (2011). 
Lentiviral vector common integration sites in preclinical models and a clinical trial 
reflect a benign integration bias and not oncogenic selection. Blood 117: 5332–5339.
53.  Deichmann, A, Brugman, MH, Bartholomae, CC, Schwarzwaelder, K, Verstegen, 
MM, Howe, SJ et al. (2011). Insertion sites in engrafted cells cluster within a limited 
repertoire of genomic areas after gammaretroviral vector gene therapy. Mol Ther 19: 
2031–2039.
54.  Kustikova, O, Fehse, B, Modlich, U, Yang, M, Düllmann, J, Kamino, K et al. (2005). 
Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. 
Science 308: 1171–1174.
55.  Kustikova, OS, Geiger, H, Li, Z, Brugman, MH, Chambers, SM, Shaw, CA et al. (2007). 
Retroviral vector insertion sites associated with dominant hematopoietic clones mark 
“stemness” pathways. Blood 109: 1897–1907.
56.  Shimizu, S, Nagasawa, T, Katoh, O, Komatsu, N, Yokota, J and Morishita, K (2002). 
EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in 
UT-7/GM cells induces megakaryocyte differentiation. Biochem Biophys Res Commun 
292: 609–616.
57.  Su, AI, Wiltshire, T, Batalov, S, Lapp, H, Ching, KA, Block, D et al. (2004). A gene atlas 
of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci USA 
101: 6062–6067.
58.  Cassani, B, Montini, E, Maruggi, G, Ambrosi, A, Mirolo, M, Selleri, S et al. (2009). 
Integration of retroviral vectors induces minor changes in the transcriptional activity of 
T cells from ADA-SCID patients treated with gene therapy. Blood 114: 3546–3556.
59.  Recchia, A, Bonini, C, Magnani, Z, Urbinati, F, Sartori, D, Muraro, S et al. (2006). 
Retroviral vector integration deregulates gene expression but has no consequence 
on the biology and function of transplanted T cells. Proc Natl Acad Sci USA 103: 
1457–1462.
60.  Baum, C (2011). Parachuting in the epigenome: the biology of gene vector insertion 
profiles in the context of clinical trials. EMBO Mol Med 3: 75–77.
61.  Schmidt, M, Schwarzwaelder, K, Bartholomae, C, Zaoui, K, Ball, C, Pilz, I et al. (2007). 
High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-
PCR). Nat Methods 4: 1051–1057.
62.  Gabriel, R, Eckenberg, R, Paruzynski, A, Bartholomae, CC, Nowrouzi, A, Arens, A et al. 
(2009). Comprehensive genomic access to vector integration in clinical gene therapy. 
Nat Med 15: 1431–1436.
63.  Kustikova, O, Brugman, M, Stahlhut, M, Bartels, S, Schiedlmeier, B, Li, Z et al. (2009). 
Longitudinal analysis of insertional mutants in a murine model of hematopoietic stem 
cell transplantation (Meeting Abstract). Hum Gene Ther 20: 1507–1508.
64.  Paruzynski, A, Arens, A, Gabriel, R, Bartholomae, CC, Scholz, S, Wang, W et al. (2010). 
Genome-wide high-throughput integrome analyses by nrLAM-PCR and  
next-generation sequencing. Nat Protoc 5: 1379–1395.
65.  Brady, T, Roth, SL, Malani, N, Wang, GP, Berry, CC, Leboulch, P et al. (2011).  
A method to sequence and quantify DNA integration for monitoring outcome in gene 
therapy. Nucleic Acids Res 39: e72.
66.  Gillet, NA, Malani, N, Melamed, A, Gormley, N, Carter, R, Bentley, D et al. (2011).  
The host genomic environment of the provirus determines the abundance of HTLV-1-
infected T-cell clones. Blood 117: 3113–3122.
67.  Kircher, M and Kelso, J (2010). High-throughput DNA sequencing–concepts and 
limitations. Bioessays 32: 524–536.
68.  Wu, X, Luke, BT and Burgess, SM (2006). Redefining the common insertion site. 
Virology 344: 292–295.
69.  de Ridder, J, Uren, A, Kool, J, Reinders, M and Wessels, L (2006). Detecting statistically 
significant common insertion sites in retroviral insertional mutagenesis screens.  
PLoS Comput Biol 2: e166.
70.  Cattoglio, C, Pellin, D, Rizzi, E, Maruggi, G, Corti, G, Miselli, F et al. (2010). 
High-definition mapping of retroviral integration sites identifies active regulatory 
elements in human multipotent hematopoietic progenitors. Blood 116:  
5507–5517.
71.  Presson, AP, Kim, N, Xiaofei, Y, Chen, IS and Kim, S (2011). Methodology and 
software to detect viral integration site hot-spots. BMC Bioinformatics 12: 367.
72.  Ciuffi, A, Llano, M, Poeschla, E, Hoffmann, C, Leipzig, J, Shinn, P et al. (2005). A role 
for LEDGF/p75 in targeting HIV DNA integration. Nat Med 11: 1287–1289.
73.  Lewinski, MK, Bisgrove, D, Shinn, P, Chen, H, Hoffmann, C, Hannenhalli, S  
et al. (2005). Genome-wide analysis of chromosomal features repressing human 
immunodeficiency virus transcription. J Virol 79: 6610–6619.
74.  Brady, T, Agosto, LM, Malani, N, Berry, CC, O’Doherty, U and Bushman, F (2009). HIV 
integration site distributions in resting and activated CD4+ T cells infected in culture. 
AIDS 23: 1461–1471.
75.  Ocwieja, KE, Brady, TL, Ronen, K, Huegel, A, Roth, SL, Schaller, T et al. (2011). HIV 
integration targeting: a pathway involving Transportin-3 and the nuclear pore protein 
RanBP2. PLoS Pathog 7: e1001313.
76.  Cherepanov, P, Maertens, G, Proost, P, Devreese, B, Van Beeumen, J, Engelborghs, Y 
et al. (2003). HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 
protein in human cells. J Biol Chem 278: 372–381.
77.  Llano, M, Vanegas, M, Fregoso, O, Saenz, D, Chung, S, Peretz, M et al. (2004). 
LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine 
oncoretroviral integrase proteins and is a component of functional lentiviral 
preintegration complexes. J Virol 78: 9524–9537.
78.  Urnov, FD, Rebar, EJ, Holmes, MC, Zhang, HS and Gregory, PD (2010). Genome 
editing with engineered zinc finger nucleases. Nat Rev Genet 11: 636–646.
79.  Lombardo, A, Genovese, P, Beausejour, CM, Colleoni, S, Lee, YL, Kim, KA et al. (2007). 
Gene editing in human stem cells using zinc finger nucleases and integrase-defective 
lentiviral vector delivery. Nat Biotechnol 25: 1298–1306.
80.  Urnov, FD, Miller, JC, Lee, YL, Beausejour, CM, Rock, JM, Augustus, S et al. (2005). 
Highly efficient endogenous human gene correction using designed zinc-finger 
nucleases. Nature 435: 646–651.
81.  Gabriel, R, Lombardo, A, Arens, A, Miller, JC, Genovese, P, Kaeppel, C et al. (2011).  
An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat Biotechnol 
29: 816–823.
82.  Wada, H, Masuda, K, Satoh, R, Kakugawa, K, Ikawa, T, Katsura, Y et al. (2008). Adult 
T-cell progenitors retain myeloid potential. Nature 452: 768–772.
83.  Bell, JJ and Bhandoola, A (2008). The earliest thymic progenitors for T cells possess 
myeloid lineage potential. Nature 452: 764–767.
84.  Doulatov, S, Notta, F, Eppert, K, Nguyen, LT, Ohashi, PS and Dick, JE (2010). Revised 
map of the human progenitor hierarchy shows the origin of macrophages and 
dendritic cells in early lymphoid development. Nat Immunol 11: 585–593.
85.  Adolfsson, J, Månsson, R, Buza-Vidas, N, Hultquist, A, Liuba, K, Jensen, CT et al. (2005). 
Identification of Flt3+ lympho-myeloid stem cells lacking erythro-megakaryocytic 
potential a revised road map for adult blood lineage commitment. Cell 121: 295–306.
86.  Kawamoto, H, Wada, H and Katsura, Y (2010). A revised scheme for developmental 
pathways of hematopoietic cells: the myeloid-based model. Int Immunol 22: 65–70.
87.  Wang, GP, Berry, CC, Malani, N, Leboulch, P, Fischer, A, Hacein-Bey-Abina, S et al. 
(2010). Dynamics of gene-modified progenitor cells analyzed by tracking retroviral 
integration sites in a human SCID-X1 gene therapy trial. Blood 115: 4356–4366.
88.  Dykstra, B, Kent, D, Bowie, M, McCaffrey, L, Hamilton, M, Lyons, K et al. (2007). 
Long-term propagation of distinct hematopoietic differentiation programs in vivo.  
Cell Stem Cell 1: 218–229.
89.  Gerrits, A, Dykstra, B, Kalmykowa, OJ, Klauke, K, Verovskaya, E, Broekhuis, MJ et al. 
(2010). Cellular barcoding tool for clonal analysis in the hematopoietic system. Blood 
115: 2610–2618.
90.  Lu, R, Neff, NF, Quake, SR and Weissman, IL (2011). Tracking single hematopoietic 
stem cells in vivo using high-throughput sequencing in conjunction with viral genetic 
barcoding. Nat Biotechnol 29: 928–933.